Phase 2 N=103 A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
Breast Cancer
Primary: Best Tumor Response — 0; 0; 8; 20 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=153 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. — 56; 76; 94; 0 percentage of subjects — p=<0.001
Phase 2 N=232 Long-Term Safety of Febuxostat in Subjects With Gout.
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. — 50; 93; 65; 82 percentage of subjects
Phase 2 N=48 Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Multiple Myeloma · Stem Cell Transplantation
Primary: Response Rate — 11; 36 Participants
Phase 2 N=15 Human Fibrinogen - Pharmacokinetics
Fibrinogen Deficiency
Primary: Maximum Clot Firmness (MCF) — 0; 8.9 millimeters — p=<0.0001
Phase 2 N=14 Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
Puberty, Precocious
Primary: Change in Growth Rate (cm/Year) — -1.62 cm/year — p=0.278
Phase 2 N=35 Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms
Aortic Aneurysm, Abdominal
Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003
Phase 2 N=707 Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)
Seasonal Allergic Rhinitis
Primary: Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15 — -3.29; -3.36; -2.97; -2.44 units on a scale — p=0.002
Phase 2 N=85 Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
HIV Infections
Primary: Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF)) — -1.43; -1.55; -1.47 Log10 copies/mL — p=0.997
Phase 2 N=72 ACAM 3000 MVA at Harvard Medical School
Smallpox
Primary: Number of Participants Reporting Moderate or Greater Solicited Local Reactions — 3; 0; 1; 6 Participants
Phase 2 N=107 Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Carcinoma, Renal Cell Metastasis
Primary: Objective Response (Complete Response[CR] + Partial Response[PR]) in Subjects — 15; 6 participants
Phase 2 N=84 G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Lymphoma
Primary: CD34+ Cells/kg in Blood Stem Cells — 7.5; 10.34 CD34+ cells/kg
Phase 2 N=105 Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
Chronic Hepatitis B
Primary: Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 — 75.5; 69.2 percentage of participants — p=.544
Phase 2 N=761 Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)
Rheumatoid Arthritis
Primary: Proportion of Patients Who Met the ACR20 Responder Index Criteria — 28.57; 35.06; 37.75; 38.57 Proportion of Patients — p=<0.001
Phase 2 N=63 Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Safety and Tolerability as Defined by the Number of Subjects With Flu-like Syndrome, Fever, Myalgia, Injection Site Reactions, Injection Site Reactions Pain, Asthenia…